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Results: Primary PTCA Thrombolysis
(l-year follow-up) (N ~ 152) IN = 166) P
Recurrent ischemia 12(8%) 54(33%) <0.0001
Recurrent MI 4(3%) 16(10%) <0.025
Mortality 7(5%) 4(2%) ns
Reocclusion rate 7(5%) 58 (35%) <0.0001
Mean diam, stenosis angio 1 27 ± 15% 56 ± 12% <0.0001
Mean diam. stenosis angio 2 35 ± 22% 68 ± 28% <0.0001
without reocclusion 31 ± 22% 48 ± 15% <0.0001
PTCA t-PA
Group A Group B Group A Group B
Time (mins) (n ~ 36) (n ~ 159) In ~ 38) (n ~ 162)
chest pain onset to randomization 211 ± 129 173± 116* 258 ± 179 183± 139t
randomization to t-PA bolus N/A N/A 34 ± 25 31 ± 22
randomization to cath lab arrival 43 ± 20 39 ± 18 N/A N/A
cath lab arrival to first angiogram 21 ± 9 20 ± 11 N/A N/A
first angiogram to reperfusion 19 ± 14 20 ± 24 N/A N/A
Hospital events
PTCA success 91.7% 94.3% N/A N/A
Death 5.6% 1,9% 7,9% 6.2%
Death or reinfarction 13.4% 3.1%§ 18.4% 105%£
Recurrent ischemia 16.7% 88%£ 34.2% 26.5%
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Is Primary Angioplasty Less Effective in Patients with
Acute Myocardial Infarction Presenting in the Early
Morning Hours?
Gregg W. Stone, Cindy L. Grines, Kevin F. Browne, Jean Marco, Donald Rothbaum,
James O'Keefe, Paul Overlie, Brian Donohue, Sylvia Puchrowicz, William W. O'Neill
£1 Camino Hospital, Mountain View- CA; William Beaumont Hospital, Royal Oak, MI
Concern has been expressed that delays in physician and cath lab mobiliza-
tion may adversely affect the feasibility and outcome of a primary angioplasty
strategy in pts with acute MI presenting in the early morning hours. In the
PAMI Trial, 395 pts within 12 hours onset of MI were prospectively random-
ized to t-PA (n = 200) vs. primary PTCA (n = 195). Demographic characteris-
tics were similar between pts presenting between 12 MN and 6 AM (Group
A) and 6 AM to 12 MN (Group B). Outcomes appear below:
Conclusion: Not only lesion diameter stenosis at first and second angiog-
raphy, but also reocclusion rate is much better with primary PTCA than with
thrombolysis. Apart from the very high reperfusion rate by PTCA for acute MI,
the better short and long term vessel status might be an additional factor for
the improved outcome.
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Prehospital thrombolysis preserves LV function, but its impact on long-term
outcome has not yet been reported. We followed for 2-7 years, 362 patients
(pts) who received IV thrombolysis since prehospital strategy was started in
Jerusalem. CHF as judged by clinical symptoms and exercise performance
were compared between 68 pts who received prehospital streptokinase, at
1.2 ± 0.6 hours of chest pain onset (group II and 294 pts with in-hospital lysis
after 2.2 ± 1.0 hours (group II).
The difference in LV function measured at 1 week contrast ventriculogra-
phy was small - Group 1- EF 58 ± 15% vs Group II - 55 ± 14%, but a
striking and significant change was observed in CHF disability (NYHA Grade
II-IV) prevalence at follow-up.
Prehospital Thrombolysis in Acute MI Prevents
Symptoms of Congestive Heart Failure - A
Long-term Follow-up Study
A. Teddy Weiss, Dan Gilon, Iris Shviro, Dan Sapoznikov, Shimon Rosenheck,
Morris Mosseri, Chaim Lotan, Yoseph Rozenman, Mervyn S. Gotsman Cardiology
Department, Hadassah Hospitals, Jerusalem, Israel
arrival. and either 0 waves or LBBB on the initial ECG, to predict mortality at
28 days and 1 year after MI.
The model was developed in 5781 pts in the MONICA data base (1984--93)
who were <65 yo, seen 1-24 hrs after symptom onset, had an ECG and were
admitted to CCU. The model was then tested in another 1000 pts. Morbidity
and mortality at 28 days and 1 year was then examined in relation to risk
Score.
Results: Overall mortality at 28 days and 1 year was 4.2% and 7.0%. The
modelidentified 60% ofpts <60 yo at very low risk (Score = 0; Mortality 1%
at 28 days and <2% at 1 year), and proved equally sensitive, specific (90%)
and predictive of survival (99%) in the test group. Of the 2562 pts with either
ST elevation or LBBB on the initial ECG, 46% had a Score = O. In these pts
n was not associated with a reduction in mortality (0.9% vs 1.0%) or heart
failure (2.5%) at 28 days. In contrast, in pts with ST elevation or LBBB and a
Score> 0, n was associated with an absolute reduction in mortality at 28
days (4.6% vs 10.6%*) and 1 year (6.1 % vs 16.1 %*); *p < 0.01.
Conclusion: In pts presenting with MI, it is possible to readily identify those
at very low (1 %) risk of death in whom the absolute benefit of n may be out
weighed by the absolute risk of treatment.
Similar significant changes between the two groups were observed for
other complaints: pulmonary edema, orthopnea, paroxysmal nocturnal dys-
pnea, nocturia, peripheral edema, fatigue and angina pectoris.
Thus, time gain through prehospital lysis prevents CHF symptoms and
long-term disability and justifies more extensive use of early thrombolysis.
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Better Vessel Status with Less Reocclusion at 3
Months as Additional Mechanism for Improved
Outcome of Primary Angioplasty for Acute
Myocardial Infarction
Gerrit Veen, Menko Jan de Boer, Felix Zijlstra, Freek WA. Verheugt. Free University
Hospital, Amsterdam, Hospital De Weezenlanden, Zwolle, The Netherlands
Primary angioplasty IPTCA) for acute myocardial infarction (MI) is associated
with improved clinical outcome (less recurrent ischemia and myocardial in-
farction), when compared to thrombolytic therapy. We sought to determine,
whether these differences were related to differences in angiographic out-
come during follow-up.
In the Zwolle-trial primary PTCAwas compared to streptokinase treatment.
However, in the thrombolysis group only a follow-up angiography was per-
formed. Therefore, in these patients (pts) successful reperfusion and reoc-
c1usion rate could not be determined.
In this report we compared quantitative angiographic and clinical follow-
up data of the pts randomized to primary angioplasty in the Zwolle-trial with
data of the APRICOT-trial, in which all pts received thrombolysis. Both study
groups had angiographically documented reperfusion of the infarct-related
artery and underwent a second angiography at 3 months. There were no
important differences in baseline characteristics.
*p < 0.09: t P~ 0.005: §p = 0.008: £p < 0.18. All other p ~ NS
Conclusions. Time to presentation is prolonged in pts with MI in the early
morning hours. No delays occur, however, in cath lab mobilization, PTCA per-
formance or success. Further studies are required to explain the apparently
worse prognosis of pts presenting between 12 MN and 6AM in this trial.
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1778-51 Timing and Mechanism of Death After Direct
Angioplasty for Acute Myocardial Infarction
Bruce Brodie, Thomas Stuckey, Richard Weintraub, Denise Muncy,
Charles Hansen, E. Joseph LeBauer, Thomas Kelly, Jonathan Berry. The Moses H.
Cone Memorial Hospital, Greensboro, N. C.
Of 907 pts with acute myocardial infarction treated with direct angioplasty
(PTCA) from 1984--93, 78 pts (86%1 died within 30 days. Of the 78 pts, 35
(45%) had cardiogenic shock prior to intervention, and an additional 4 (5%)
presented with acute pulmonary edema without shock. Twenty-eight pts
(36%1 died on day 0, 9 (12%) on day 1, and 10 (13%) on day 2. The mecha-
nisms of death were pump failure in 49 (63%), reinfarction in 7 (9%), rupture
in 5 (6.4%), arrhythmia in 3 138), other cardiac causes in 2 (2.6%), and non-
cardiac causes in 12 (15%). Almost all the early deaths (27/28) were due to
pump failure. Of 78 pts who died, 28 (36%) developed hemodynamic deteri-
oration or cardiac arrest immediately after reperfusion and 13 of these died
in the cath lab. Hemodynamic deterioration and cardiac arrest occurred less
often when intra-aortic balloon pumping (IABP) was initiated before PTCA vs
after PTCA or not at all (2/18 (11 %) vs 26/60 143%), P < 0.03).
Conclusion: Mortality after PTCA, like thrombolytic therapy, is the highest
in the first 24 hours, and this is almost always due to pump failure. Unlike
thrombolytic therapy, the incidence of death from rupture and arrhythmias
is relatively low. Early mortality is high partially due to the high incidence of
cardiogenic shock in our population, but some of the early mortality may be
related to hemodynamic deterioration occurring immediately after reperfu-
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sion. The use of IABP before PTCA in selected pts may help to prevent this
post-reperfusion hemodynamic instability.
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1778-61 Timing, Mode and Predictors of Death After Direct
Angioplasty for Acute Myocardial Infarction
Rafti K. Krikorian, James L. Vacek, Thomas L. Rosamond, Gary D. Beauchamp Mid
America Heart Institute and St, Luke's Hospital, Kansas City. MO
The timing and mechanisms of early (30 day) mortality in 330 consecutive
patients (pts) treated with direct angioplasty less than 12 hours after onset
of myocardial infarction (MI) without antecedent thrombolysis were studied.
There were 38 deaths (11,5% of pts). with a majority being due to cardio-
genic shock (76%). Other causes included acute closure (11 %). death after
emergency bypass surgery (5%), ventricular arrhythmias (5%), and respira-
tory failure (3%1. Therefore 37 of 38 deaths (97%) were cardiac. No deaths
from stroke or cardiac rupture were seen, in contrast to trials of thrombolytic
agents, Most deaths were seen early, with 47% occurring within 1 day, 35%
from days 2-7, and 18% from days 8-30, Deaths from cardiogenic shock was
the most common cause of death throughout this period: 83% of deaths in
days 0-3, 88% of deaths in days 4-6, and 43% of deaths in days 8-30.
The pts who died were significantly older (69 ± 11 vs. 61 ± 11 years, p <
0,0001), had more frequent direct angioplasty failure 124% vs 7%, P < 0.05),
reduced ejection fraction (31 ± 17% vs 44 ± 14%, P < 0.0001), more multi-
vessel disease (74% vs 54%, P < 0.05), and more anterior infarcts (74% vs
42%, P < 0.0005) than survivors, Gender, prior MI. and prior bypass surgery
did not effect mortality.
Conclusions: Cardiogenic shock is the most common cause of early death
after direct angioplasty for MI. Pts with one or more risk factors for early
death may benefit from additional myocardial salvage or revascularization
efforts in the early post-infarct period. Causes of death after direct angio-
plasty appear to be different than those described after lytic therapy for MI.
Specifica I'y, myocardial rupture and intracranial hemorrhage were not causes
of death in this study population.
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Wednesday, March 22,1995,8:30 a.m.-10:00 a.m.
Ernest N. Morial Convention Center, Room 64
8:30
1779-1 1 Vasodilator Effects of the Endothelin-1 Receptor
Antagonist Bosentan in Patients with Severe Chronic
Heart Failure
Wolfgang Kiowski, Osmund Bertel, Gabor Sotsch, Patrick Hunziker, Peter MOiler,
Rita Schmitt, Jonghun Kim, Erwin Oechslin, Divisions of Cardiology, University and
Triemli Hospital, Zurich, Switzerland
Patients (pts) with chronic heart failure (CHF) have increased plasma levels of
the endothelial vasoconstrictor endothelin-l (ET) but it is unknown whether
ET plays a role in the maintenance of vascular tone. Therefore, 24 pts with
CHF NYHA III-IV were randomised in a double blind study to either Bosentan
(Ro 47-0203, a potent ET-A and ET-B receptor antagonist; 100 mg followed
60 min later by 200 mg iv over 15 min each) or placebo (P1), Hemodynam-
ics (Swan-Ganz and arterial catheters) were obtained after discontinuation
of ACE-inhibitors (>4 plasma half lives). Pl did not result in any significant
hemodynamic changes. Results for the Bosentan group are given in the ta-
ble.
Bos100mg Bas 200 mg p<
Time (min) 0 20 40 60 20 40 60
MAP 64 79 77 78 76 76 75 0.001
CI 2.13 2.41 2.42 2.41 2.64 255 243 0.001
SVR 1479 1248 1224 1236 1100 1140 1182 0.001
PCWP 22.5 21.8 21.2 20.8 19.2 18.9 19.8 0.001
RA 11.1 10.0 95 9.5 9.3 8.6 91 0.001
HR 86 86 85 85 83 84 85 n.s.
MAP: mean arterial pressure (mmHg), CI: cardiac index (1/min/m2l, SVR:
systemic vascular resistance (dyn.sec,cm-5), PCWP: pulmonary capillary
wedge pressure (mmHg), RA: right atrial pressure (mmHgl, HR: heart rate
(beats/min); p values for repeated measures ANOVA. Bosentan was well tol-
erated and resulted in sustained systemic and venous vasodilation without
reflex tachycardia and improved cardiac performance. The results, therefore,
demonstrate that ET is involved in the regulation of vascular tone and that
inhibition of its vascular effects may be beneficial in CHF.
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1779-21 L-Arginine Does not Acutely Influence Endothelial
Function in Either Resistance or Conduit Arteries of
Dogs with Pacing induced Congestive Heart Failure
y. Chandrashekhar, Zona McKenzie, Daniel Nelson, Stephen Archer, Inder
S. Anand. VA Medical Center & University of Minnesota, Minneapolis
Endothelial function is thought to be abnormal in CHF and this may be due to
inadequate endothelial derived relaxing factor (EDRF). L-Arginine, a precur-
sor of EDRF, is therefore postUlated to improve endothelial function in CHF.
We studied the effect of L-Arginine (3 mM/min) on endothelial functions in
the resistance and conduit arteries (1.8-2.2 mm in size) of dogs before (n =
12) and after (n = 6) inducing heart failure by rapid ventricular pacing, En-
dothelial function in resistance vessels was assessed by measuring resting
and acetylcholine (Ach: 10-5 to 10-8 M) stimulated hind limb blood flow
(HLBFI and vascular resistance (HLVR) using electromagnetic flow probe be-
fore & during intra-arterial L-arginine infusion (3 mM/min). Conduit arteries
were studied by measuring isometric tension in a tissue bath system; the
effects of serial doses of acetylcholine (10-5 to 10-8 M) & sodium nitroprus-
side (SNP: 10-5 to 10-8 M) were evaluated with (1 mM) &without L-arginine
in the bath. These effects were repeated in the presence L-NAME (10-5 to
10-8 M). L-Arginine did not influence the HLBF or HLVR at rest or following
stimulation with Ach (peak % change in HLVR withfwithout arginine: control
71 ± 7 vs 68 ± 4, P ~ 0.24 & CHF 82 ± 6 vs 81 ± 3, p = 0.79) or SNP, both
in the control or CHF dogs. While Ach had a significantly greater effect in
the CHF rings compared to controls (34 vs 14%, P = 0.01), adding L-arginine
did not affect developed isometric tension in rings from the conduit arteries
before (peak change after Ach withfwithout arginine 16 ± 3% vs 10 ± 4%,
P = 0.25) or while in heart failure (33 ± 8 to 36 ± 16%, P = 0.85). Further,
L-arginine did not affect the response to L-NAME in either group of dogs (p
= 0.65 in controls & p = 0.16 in CHF). These data suggest that L-arginine ad-
ministration acutely does not influence endothelial function in either conduit
or resistance arteries in normal or heart failure dogs.
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L-arginine Acutely Reduces Increased Ventilatory
Cost of Carbon Dioxide Excretion on Exercise in
Chronic Heart Failure: Evidence of Pulmonary
Endothelial Dysfunction?
Adrian P. Banning, Bernard Prendergast. Stuart Elbourne, David Tyler, Andrew
H. Henderson Department of Cardiology, University of Wales College ofMedicine,
Cardiff. UK
Patients with chronic heart failure (CHF) have an increased ventilatory cost
of C02 excretion on exercise (the linear VENC02 slope - m). This repre-
sents mismatch of perfusion to ventilation ION) during exercise and may re-
flect dysfunction of pulmonary endothelium and microvessels, as is present
in systemic vessels in CHF. We have studied the effect of L-arginine, sub-
strate for endogenous endothelial nitric oxide (NO). on slope m in CHF. Male
patients (n = 11) with stable NYHA class lib or III CHF were enrolled into
a cross-over study of iv I-arginine (ARC) (0,5 mglkg over 30 min) vs. sublin-
gual nifedipine (endothelium independent vasodilator). Patients had no other
known risk factors for endothelial dysfunction, no inducible myocardial is-
chaemia and all were receiving ACE inhibitors and diuretics. Patient groups
were characterised according to peak V02 < 15 mllkg/min. Exercise tests
were performed 15 min pre and immediately post infusion. Outcome mea-
sures were m before and after treatment, exercise duration (ExD, secs) and
peak oxygen consumption (V02. mllkg/min).
m pre Post arginine m pre Post nifedipine
m Ex D V02 m ExD V02
V02 < 15 41 ± 7 34 ± 7* 340 ± 90 14± 1 37 ± 5 36 ± 6 360 ± 50 13± 1
V02> 15 31 ± 2 31 ± 2 360 ± 50 18± 1 31 ± 3 30 ± 1 690 ± 30 18± 1
*p < 0.05, pre vs post infusion
Mean blood pressure during exercise was similar following both treat-
ments.
Patients with peak V02 < 15 had an elevated VENC02 slope which was
reduced by ARG. These preliminary data suggest that exercise related ON
mismatch in severe CHF is acutely reversible and may involve endothelial
dysfunction.
